TrialEuropean journal of haematology2020

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.

Ajeeta B Dash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.